Constitutive NOTCH3 signaling promotes the growth of basal breast cancers

Cancer Research

Volumn 77, Issue 6, 2017, Pages 1439-1452

  Choy, Lisa ^a   Hagenbeek, Thijs J ^a   Solon, Margaret ^a   French, Dorothy ^a   Finkle, David ^a   Shelton, Amy ^a   Venook, Rayna ^a   Brauer, Matthew J ^a   Siebel, Christian W ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH3 RECEPTOR; PROTEIN JAGGED 1; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL CARCINOMA CELL; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; ID4 GENE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; ONCOGENE; ONCOGENE C MYC; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; APOPTOSIS; BASAL CELL CARCINOMA; BREAST TUMOR; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS, BASAL CELL; RECEPTOR, NOTCH3; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015973172     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1022     Document Type: Article

References (42)

1. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc. 2013.
2. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of Notch. Nat Struct Mol Biol 2007;14:295-300.
3. Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol Cell Biol 2004;24:9265-73.
4. Wu JK, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J, et al. A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis 2010;13:15-23.
5. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
6. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012;23:458-64.
7. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
8. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008; 111:439-48.
9. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011;17:1646-51.
10. Lafkas D, Rodilla V, Huyghe M, Mourao L, Kiaris H, Fre S. Notch3 marks clonogenic mammary luminal progenitor cellsin vivo. J Cell Biol 2013; 203:47-56.
11. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and inducesmammary tumors.AmJ Pathol 2006;168:973-90.
12. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29:2013-23.
13. Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, et al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clin Cancer Res 2015;21:1487-96.
14. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008;68:1881-8.
15. Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000;20:1825-35.
16. Krejci A, Bray S. Notch activation stimulates transient and selective binding of Su(H)/CSL to target enhancers. Genes Dev 2007;21:1322-7.
17. Tiyanont K, Wales TE, Aste-Amezaga M, Aster JC, Engen JR, Blacklow SC. Evidence for increased exposure of the Notch1 metalloprotease cleavage site upon conversion to an activated conformation. Structure 2011;19: 546-54.
18. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
19. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 2010;26:873-81.
20. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
21. Huntzicker EG, Hotzel K, Choy L, Che L, Ross J, Pau G, et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology 2015;61:942-52.
22. Lin MH, Kopan R. Long-range, nonautonomous effects of activated Notch1 on tissue homeostasis in the nail. Dev Biol 2003;263:343-59.
23. Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016;35:6077-86.
24. Lafkas D, Shelton A, Chiu C, de Leon Boenig G, Chen Y, Stawicki SS, et al. Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung. Nature 2015;528:127-31.
25. Wood S, Feng J, Chung J, Radojcic V, Sandy-Sloat AR, Friedman A, et al. Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoralmechanisms in a mouse model of heart transplantation. J Immunol 2015;194:2899-908.
26. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7.
27. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS One 2013;8:e67306.
28. Li K, Li Y, WuW, Gordon WR, Chang DW, Lu M, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 2008;283:8046-54.
29. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096-109.
30. Krebs LT, Deftos ML, Bevan MJ, Gridley T. The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway. Dev Biol 2001;238:110-9.
31. VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development (Cambridge, England) 2012;139:488-97.
32. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
33. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, et al. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 2013;32:554-63.
34. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
35. Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, et al. Notch promotes recurrence of dormant tumor cells following HER2/neutargeted therapy. J Clin Invest 2015;125:2484-96.
36. Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov 2014;4:1154-67.
37. Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 2010;123:113-24.
38. Mosquera JM, Sboner A, Zhang L, Chen CL, Sung YS, Chen HW, et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer 2013;52:1075-87.
39. Hori K, Sen A, Kirchhausen T, Artavanis-Tsakonas S. Synergy between the ESCRT-III complex and Deltex defines a ligand-independent Notch signal. J Cell Biol 2011;195:1005-15.
40. Xu X, Choi SH, Hu T, Tiyanont K, Habets R, Groot AJ, et al. Insights into autoregulation of Notch3 from structural and functional studies of its negative regulatory region. Structure 2015;23:1227-35.
41. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-6.
42. Junankar S, Baker LA, Roden DL, Nair R, Elsworth B, Gallego-Ortega D, et al. ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nat Commun 2015;6:6548